CMS Expands TAVR Access, Covers Asymptomatic Aortic Stenosis

The Centers for Medicare & Medicaid Services (CMS) has significantly expanded access to transcatheter aortic valve replacement (TAVR) by removing the Coverage with Evidence Development (CED) requirement for symptomatic severe aortic stenosis (AS). This policy change, effective immediately, means that patients with symptomatic severe AS no longer need to participate in clinical trials or specific data collection programs to be eligible for TAVR coverage.

Furthermore, CMS has introduced new coverage for TAVR in patients with asymptomatic severe AS. This represents a major shift, as previously, TAVR was primarily indicated for patients who were symptomatic and considered high-risk for surgical valve replacement. The decision to cover asymptomatic cases acknowledges the growing body of evidence suggesting that TAVR can offer significant benefits, including improved survival and quality of life, even in patients who do not yet exhibit symptoms. This expansion is expected to increase the number of patients eligible for TAVR, potentially leading to earlier intervention and better long-term outcomes.

In parallel, CMS has also updated its guidance regarding percutaneous coronary intervention (PCI) in very elderly patients. Specifically, the agency has clarified coverage for PCI in individuals aged 90 years and older. This update aims to provide clearer parameters for physicians when considering PCI for this vulnerable patient population, ensuring that appropriate clinical considerations and evidence-based practices are followed. The agency's focus on this age group reflects the increasing lifespan and the complex cardiovascular needs of older adults.

Additionally, CMS has established coverage for point-of-care troponin testing. Troponin is a protein released into the bloodstream when the heart muscle is damaged, making troponin tests crucial for diagnosing heart attacks. Point-of-care testing allows for rapid results to be obtained at the patient's bedside or in an emergency setting, rather than requiring samples to be sent to a central laboratory. This can significantly speed up the diagnostic process, enabling faster treatment decisions and potentially improving patient outcomes in acute cardiac events. The inclusion of point-of-care troponin testing under CMS coverage underscores the agency's commitment to facilitating timely and efficient cardiac care.